Aptevo Therapeutics Files S-1 for Future Offering
Ticker: APVO · Form: S-1 · Filed: Mar 3, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | S-1 |
| Filed Date | Mar 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: s-1, registration-statement, pharmaceuticals, offering
Related Tickers: APVO
TL;DR
APVO filed an S-1, get ready for a potential stock offering.
AI Summary
Aptevo Therapeutics Inc. filed an S-1 registration statement on March 3, 2025, for an unspecified offering. The company, incorporated in Delaware with its principal executive offices in Seattle, Washington, operates in the pharmaceutical preparations sector. This filing indicates a potential future equity event for the company.
Why It Matters
This S-1 filing signals Aptevo Therapeutics' intention to raise capital through a future securities offering, which could impact its financial structure and growth prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company filing an S-1, the inherent risks associated with drug development, regulatory approvals, and market competition are significant.
Key Numbers
- 333-285476 — SEC File Number (Identifies this specific registration statement with the SEC.)
- 0001671584 — Central Index Key (Unique identifier for Aptevo Therapeutics Inc. in SEC filings.)
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- Marvin L. White (person) — President and Chief Executive Officer
- Sean M. Donahue (person) — Legal Counsel (Paul Hastings LLP)
- 206-838-0500 (dollar_amount) — Business Phone Number
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public. While the exact offering details are not in this excerpt, it signals Aptevo Therapeutics' intent to raise capital.
When was this S-1 filed?
This S-1 filing was filed with the Securities and Exchange Commission on March 3, 2025, and was as filed with the SEC on February 28, 2025.
What industry does Aptevo Therapeutics operate in?
Aptevo Therapeutics Inc. operates in the Pharmaceutical Preparations sector, with a Standard Industrial Classification code of 2834.
Who is the principal executive officer of Aptevo Therapeutics?
Marvin L. White is listed as the President and Chief Executive Officer of Aptevo Therapeutics Inc.
Where are Aptevo Therapeutics' principal executive offices located?
Aptevo Therapeutics Inc.'s principal executive offices are located at 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on March 3, 2025 by Marvin L. White regarding Aptevo Therapeutics Inc. (APVO).